Teladoc Stock Plunges Amid Forecast of Slower Virtual Healthcare Growth

Teladoc Health's stock plummeted after posting weaker-than-expected financial results and underwhelming guidance, marking a 95% drop from its all-time high three years ago. The company's revenue growth has decelerated for 11 consecutive quarters, with a decline in telemedicine visits in 2023. While its losses continue to narrow and free cash flow is expected to increase, the outlook for revenue growth remains modest. The stock's enterprise value is currently reasonable, but investors are looking for signs of usage growth before feeling comfortable about forward metrics.